Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT04847388 Not yet recruiting - HIV Infections Clinical Trials

Prevalence of Substance Abuse Among Anti-retroviral Treatment Naive Patients Positive for HIV Antibodies

Start date: April 2021
Phase:
Study type: Observational

Individuals use substance for mood-alerting purposes. Substance can be alcohol, cannabis, nicotine, cocaine and methamphetamine. Substance addiction/abuse is excessive use of a drug that is detrimental to self and society . These drugs are linked to risky sex behavior and they are related to unsafe sex and thereby chances are more to contracting HIV infection in two ways. Firstly, people inject drugs and shares needle; secondly, drugs impair judgment that leads to unprotected sex with infected partner. The relationship between drug use and HIV disease progression may be mediated by several factors, including immunologic and virologic conditions affecting host susceptibility, underlying comorbidities among drug users, use of antiretroviral therapy, and viral strain, as well as pharmacodynamic aspects of drug use, such as the pattern and type of drug administration and the route of administration. Laboratory based studies show exacerbation of HIV progression among patient with drug addiction.

NCT ID: NCT04846946 Not yet recruiting - HIV Infections Clinical Trials

HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: "Hey, Friend"

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

In this 24-month pilot study, we will conduct the preparation phase of a multiphase optimization strategy (MOST) to develop a culturally appropriate (for Deep South contexts, to be adolescent friendly, and to be acceptable to parents or guardians) modular HIV prevention mHealth intervention, targeting behavior change related to HIV testing, HIV prevention knowledge, and pre-exposure prophylaxis (PrEP) uptake for sexual and gender minority (SGM) adolescents, that can be seamlessly integrated into the existing school and community environments across the Deep South.

NCT ID: NCT04846595 Recruiting - HIV Infections Clinical Trials

Aspects of Vulnerability of People Living With HIV in the Alpine Arc Region

ASPEGIC
Start date: February 16, 2021
Phase: N/A
Study type: Interventional

HIV infection in France has become a chronic disease and treatment has allowed patients to increase their life expectancy. However, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. Few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. The investigators chose to consider the vulnerability of people living with HIV (PLWHA) through the measurement of a validated French quantitative score, called EPICES ("Évaluation de la précarité et des inégalités de santé dans les centres d'examens de santé ", Evaluation of precariousness and health inequalities in health examination centers).

NCT ID: NCT04840199 Not yet recruiting - HIV Infections Clinical Trials

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

ELICIT
Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

This is a placebo-controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who are on antiretroviral therapy (ART)-mediated suppression. Participants will be randomly assigned to receive either letermovir or placebo, once daily, for 48 weeks, followed by 12 weeks of observation on ART alone.

NCT ID: NCT04836091 Recruiting - HIV/AIDS Clinical Trials

Acceptability, Feasibility and Preliminary Impact of OurPlan, an mHealth HIV Prevention Intervention for Male Couples

OurPlan
Start date: March 16, 2021
Phase: N/A
Study type: Interventional

The study will evaluate the use and preliminary impact of an mHealth app for improving sexual health outcome measures among male couples by assessing whether exposure and use of the app results in improvements in participants and couples' self-reported sexual health and prevention behaviors, beliefs, and attitudes. The study will enroll both men of the couple into a randomized controlled trial. Participants/couples randomized to the intervention will have access to the app for two months while those assigned to the waitlist group will receive and have access to the app for one month. Participants will complete surveys at baseline and at month 2.

NCT ID: NCT04833829 Enrolling by invitation - HIV Infections Clinical Trials

Cross-disciplinary HIV Integrated Mental Health Support Intervention

CHIMES
Start date: November 1, 2020
Phase: N/A
Study type: Interventional

The proposed project seeks to develop and test an intervention to improve engagement in HIV and mental health care for young Black gay, bisexual and other men who have sex with men (YB-GBMSM) in Ryan White clinics.

NCT ID: NCT04827134 Not yet recruiting - HIV Infections Clinical Trials

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

Start date: April 22, 2021
Phase: Phase 1
Study type: Interventional

This study will assess the effect of food on the pharmacokinetics (PK) of pediatric formulations of TRIUMEQ (dolutegravir [DTG] 5 milligrams [mg]/abacavir [ABC] 60 mg/lamivudine [3TC] 30 mg) dispersible tablets and DOVATO (DTG 5 mg/3TC 30 mg) dispersible tablets in healthy adult participants. Additionally, safety and tolerability of these formulations will also be assessed. TRIUMEQ and DOVATO are registered trademarks of GlaxoSmithKline group of companies.

NCT ID: NCT04826562 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

Sound
Start date: April 2021
Phase: Phase 4
Study type: Interventional

An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 < 50 copies/mL

NCT ID: NCT04826094 Recruiting - HIV Infections Clinical Trials

A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

Start date: March 16, 2021
Phase: Phase 1
Study type: Interventional

This is a study of HIV vaccines. A vaccine is a medical product given to prevent certain diseases. The vaccine may educate the body to form a defensive response to try to prevent the disease from the beginning, or preventing it from taking hold of the body. This defensive response is called the immune response. The experimental vaccines in this study are Env-C Plasmid DNA and HIV Env gp145 C690 protein, given with different adjuvants. An adjuvant is a substance added to vaccines that can help make the vaccine more effective by improving the immune response, or by causing the immune response to last longer than it would without the adjuvant. The adjuvants are mixed with the vaccines and injected into muscle or placed on top of the skin. The HIV vaccines contain a piece of genetic material or a protein copied drom the HIV virus cover (Env), but they do not contain the virus itself. The vaccines cannot cause HIV infection or Acquired Immune Deficiency Syndrome (AIDS). The purpose of this study is to find out if the study vaccines with adjuvants cause side effects and are tolerable, whether humans respond (develop immune responses) to the vaccines, and how ling the effects of the study vaccines last. The study will also compare the effects of the study vaccines with adjuvants and adjuvant patch to those of placebo injections and placebo patch. The placebo will consist of saline (sterile saltwater) and will look like study vaccines, be given in the same way, but will have no active vaccine or adjuvant in it. A total of 126 participants will take part in the study and each will have up to 26 clinic visits and will be followed-up for a total of 108 weeks.

NCT ID: NCT04824131 Recruiting - HIV Infections Clinical Trials

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084

Start date: November 4, 2020
Phase: Phase 2
Study type: Interventional

This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.